What is Genvor Inc's earnings per share (EPS)?

Genvor Inc (GNVR) reported diluted earnings per share of $-0.22 for fiscal year 2025. This represents a -46.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Genvor Inc Financials

GNVR

Source SEC Filings (10-K/10-Q) Updated Feb 12, 2026 Currency USD FYE September

This page shows Genvor Inc (GNVR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GNVR FY2025 2026-05-13

GNVR’s visible mechanic is liability triage, with debt shrinking faster than the company’s capacity to rebuild liquidity.

From FY2024 to FY2025, long-term debt nearly vanished, dropping from $905K to $20K. But that cleanup did not restore flexibility: cash was only $37K and the current ratio just 0.0337x, so the balance sheet looks less burdened by term debt but still dependent on managing near-term obligations.

The improvement in equity came mainly from shrinking liabilities, not from a stronger operating asset base; total liabilities fell to $1.36M while total assets were only $46K. That means the company is becoming less underwater on paper without yet rebuilding the resources that usually support normal operations.

The capital structure also shifted pressure onto shareholders: share count expansion took outstanding shares to 29.8M from 20.0M in FY2024. Even with that added equity cushion, loss per share worsened to -$0.22 from -$0.15, implying financing activity did not translate into operating stabilization.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Genvor Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Genvor Inc's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.22

YoY-46.7%

Genvor Inc earned $-0.22 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 46.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$37K

YoY+9881.5%

Genvor Inc held $37K in cash against $20K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

30M

YoY+48.9%

5Y CAGR+8.3%

Genvor Inc had 30M shares outstanding in fiscal year 2025. This represents an increase of 48.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

GNVR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$0	$0-100.0%	$226K	N/A
SG&A Expenses	N/A	N/A	$172K	N/A	$24K+389.2%	$5K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$60K+238.1%	$18K-59.6%	$44K	N/A	$103K	N/A
Income Tax	N/A	N/A	N/A	N/A	$0	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	-$5K
EPS (Diluted)	$-0.22-46.7%	$-0.15-114.3%	$-0.07	N/A	$-0.15	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$57K0.0%	$57K	N/A	$272K+395.9%	$55K-13.6%	$63K	N/A	$44K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	$563K+200.0%	-$563K	N/A	-$578K	N/A	N/A	N/A	N/A
Interest Expense	$15K0.0%	$15K	N/A	$16K-29.6%	$23K+497.5%	$4K	N/A	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$576K+200.0%	-$576K	N/A	-$398K	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.02+200.0%	$-0.02	N/A	$-0.010.0%	$-0.01+95.8%	$-0.24	N/A	$-0.03

GNVR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$46K+28.8%	$36K-56.6%	$82K-74.0%	$316K-43.3%	$557K	$0
Current Assets	$46K+111.4%	$22K-67.3%	$66K-77.8%	$298K-44.3%	$536K	N/A
Cash & Equivalents	$37K+9881.5%	$373-99.2%	$44K-85.0%	$296K	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-22.4%	$1.7M-2.1%	$1.8M+4.5%	$1.7M-33.7%	$2.6M+14768.2%	$17K
Current Liabilities	$1.4M-22.4%	$1.7M-2.1%	$1.8M+10.2%	$1.6M-33.8%	$2.4M+14023.2%	$17K
Long-Term Debt	$20K-97.8%	$905K-31.5%	$1.3M+15.6%	$1.1M	N/A	N/A
Total Equity	-$1.3M+23.4%	-$1.7M-0.5%	-$1.7M-22.3%	-$1.4M+31.0%	-$2.0M-11557.4%	-$17K
Retained Earnings	-$26.2M-27.1%	-$20.6M-16.3%	-$17.7M-10.5%	-$16.0M-35.9%	-$11.8M-28885.7%	-$41K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$146K0.0%	$146K+218.1%	$46K-60.6%	$116K+453.3%	$21K-19.2%	$26K-26.8%	$36K+51.1%	$24K
Current Assets	$146K0.0%	$146K+218.1%	$46K-55.9%	$104K+1189.8%	$8K-36.1%	$13K-41.9%	$22K+135.8%	$9K
Cash & Equivalents	$104K0.0%	$104K+178.2%	$37K-62.4%	$99K+15334.2%	$641+10.3%	$581+55.8%	$373+164.5%	$141
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	-$914K-175.8%	$1.2M-11.3%	$1.4M-20.7%	$1.7M-18.3%	$2.1M+12.4%	$1.9M+6.7%	$1.7M+9.9%	$1.6M
Current Liabilities	$1.2M0.0%	$1.2M-11.3%	$1.4M-20.7%	$1.7M-18.3%	$2.1M+12.4%	$1.9M+6.7%	$1.7M+9.9%	$1.6M
Long-Term Debt	N/A	N/A	$20K	N/A	N/A	N/A	$905K	N/A
Total Equity	$1.1M+200.0%	-$1.1M+19.3%	-$1.3M+17.8%	-$1.6M+23.1%	-$2.1M-12.8%	-$1.8M-7.4%	-$1.7M-9.3%	-$1.6M
Retained Earnings	$26.8M+200.0%	-$26.8M-2.2%	-$26.2M+0.4%	-$26.3M-1.5%	-$25.9M-1.2%	-$25.6M-24.3%	-$20.6M-0.8%	-$20.4M

GNVR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	N/A	N/A	N/A	-$663K	$0
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	N/A	N/A	N/A	N/A	$900K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$194K+200.0%	-$194K-24.3%	-$156K+52.4%	-$327K-360.2%	-$71K-4832.9%	-$1K+92.7%	-$20K+77.0%	-$86K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$260K0.0%	$260K+176.4%	$94K-77.9%	$426K+497.9%	$71K+4214.7%	$2K-91.8%	$20K-74.1%	$77K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GNVR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.03+0.0	0.01-0.0	0.04-0.1	0.18-0.0	0.22	N/A
Debt-to-Equity	-0.02+0.5	-0.53+0.2	-0.77+0.0	-0.82+0.5	-1.28-0.3	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	54.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	395.4%+790.8pp	-395.4%	N/A	-341.7%	N/A	N/A	N/A	N/A
Current Ratio	0.120.0	0.12+0.1	0.03-0.0	0.06+0.1	0.000.0	0.010.0	0.010.0	0.01
Debt-to-Equity	-0.86+0.3	-1.14-1.1	-0.02+1.1	-1.07-0.1	-1.010.0	-1.01-0.5	-0.53+0.5	-1.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Mustgrow Biologics Corp MGROF

$25.3M

Purebase PUBC

$7.0M

Co2 Gro BLONF

$1.4M

Sustainable Green Team Ltd SGTM

$14.9M

Itronics ITRO

$2.9M

Frequently Asked Questions

How much debt does Genvor Inc have?

As of fiscal year 2025, Genvor Inc (GNVR) had $37K in cash and equivalents against $20K in long-term debt.

What are Genvor Inc's total assets?

Genvor Inc (GNVR) had $46K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Genvor Inc have outstanding?

Genvor Inc (GNVR) had 30M shares outstanding as of fiscal year 2025.

What is Genvor Inc's current ratio?

Genvor Inc (GNVR) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Genvor Inc's debt-to-equity ratio?

Genvor Inc (GNVR) had a debt-to-equity ratio of -0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Genvor Inc's debt-to-equity ratio negative or unusual?

Genvor Inc (GNVR) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Genvor Inc?

Genvor Inc (GNVR) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.